CompletedEUCTR 2006-003658-47
Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
This historical record does not confirm current site availability.
Historical research recordFranceDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- France
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Pierre Fabre Médicament - IRPF
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-003658-47
- Official title
Show the full official title
Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedFrance
Registry details
Historical country statuses
- France — Completed
Questions about this study
Who is behind this study?
The study sponsor is Pierre Fabre Médicament - IRPF.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Intranasal Esketamine Added to Standard Care for Adults at Imminent Suicide Risk
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression